期刊文献+

通心络对高血压、高血糖合并高胆固醇血症大鼠动脉的影响及机制

Effects and mechanism of Tongxinluo on arteries of rats with hypertension,hyperglycemia and hypercholestero-lemia
下载PDF
导出
摘要 目的评价通心络对高血压、高血糖合并高胆固醇血症大鼠模型动脉功能的影响及机制。方法将体重300~400 g的成年自发性高血压大鼠(SHR)32只随机分为普食组(SHR组)、对照组(模型组)、低剂量通心络(0.2 g/kg)干预组(通心络低组)、高剂量通心络(0.8 g/kg)干预组(通心络高组),另取8只正常血压大鼠作为正常组,高脂喂养4周建立动物模型。通心络干预4周后,行主动脉离体血管功能检查,用荧光定量PCR方法测定过氧化物酶体增殖物受体γ(PPAR-γ)mRNA表达。结果通心络干预后大鼠离体主动脉对乙酰胆碱、硝普钠引起的舒张反应增强,通心络高组对A23187的舒张反应增强(P<0.05),通心络剂量依赖性增加PPAR-γ基因表达。结论通心络干预具有保护血管内皮功能及逆转血管平滑肌功能障碍等作用,其机制可能与激活PPAR-γ基因表达有关。 Objective To study the effects and mechanism of Tongxinluo on arteries of rats with hypertension, hyperglycemia and hypercholesterolemia. Methods Adult spontaneously hyperteasive rats (SHR, weighing 300 N 400 g) were randomly divided into 4 groups: SHR group (n = 8, with normal diet), model group (n =8, with high fat diet), low - dose Tongxinluo (LT) group ( n = 8, treated with Tongxinluo of 0. 2 g/kg) and high - dose (HT) group ( n = 8, treated with Tongxinluo of 0. 8 g/kg). Meanwhile, 8 Wistar rats fed with normal diet were set as normal control group. SHR model was constructed with high cholesterol diet for 4 weeks. Acetylcholine, A23187 and sodium nitroprusside were applied for artery ring study. RT - PCR was performed of quantification of peroxisome proliferator - activated receptor gam- ma (PPAR - γ) gene expression. Results Comparing with model group, significant magnification of cumulative concen- tration - dependent relaxation to acetylcholine and sodium nitroprusside was observed both in LT and HT groups, while significant amplified relaxation of A23187 was only observed in HT group (P 〈 0. 05 ). The gene expression of PPAR γ was significantly increased by Tongxinluo follow dose - dependently manners. Conclusion Tongxinluo superfine powders pro- tect aorta endothelial function and reverse disturbances of smooth muscle cells, probably via induction of gene expression of PPAR - γ.
出处 《广东医学》 CAS CSCD 北大核心 2011年第12期1505-1508,共4页 Guangdong Medical Journal
基金 国家973项目(编号:2005CB523305) 广东省自然科学基金资助项目(编号:8451008002001091 9151064101000063) 广东省医学科学基金资助项目(编号:A200810)
关键词 高血压 高血糖 高胆固醇血症 通心络 动脉 过氧化物酶体增殖物受体γ hypertension hyperglycemia hypereholesterolemia Tongxinluo artery peroxisome proliferator -activated receptor γ
  • 相关文献

参考文献7

  • 1黄晓忠,刘晓颖,余细勇,董晖,费洪文,吴伟康,吴以岭,林曙光.通心络对高血压、高血糖合并高胆固醇血症大鼠的治疗作用[J].中国中药杂志,2011,36(2):224-227. 被引量:19
  • 2YUSUF H R, GILES W H, CROFT J B, et al. Impact of multiple risk factor profiles on determining cardiovascular disease risk [ J ]. Prey Med, 1998, 27(1) : 1 -9.
  • 3GRUNDY S M, CLEEMAN J I, DANIELS S R, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute scientific statement[J]. Circulation, 2005, 112(17) : 2735 -2752.
  • 4JOHNSON A, PHELP D T, FERRO T J. Tumor necrosis factor-al- pha decreases pulmonary artery endothelial nitrovasodilator via protein kinase C[J]. AmJ Physiol, 1994, 267 (3 Pt 1): L318-L325.
  • 5ZAMBON A, GERVOIS P, PAULETTO P, et al. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR - alpha activators: clinical and experimental evidence [ J ]. Arterioscler Thromb Vasc Biol, 2006, 26 (5) : 977 - 986.
  • 6TAO L, LIU H R, GAO E, et al. Rosiglitazone improves endothe- / lial function in rabbits with hypercholesterolemia by reducing oxi-dative stress and preserving NO/cGMP signaling[ J]. Acad Emerg Med, 2003, 10(5) : 425.
  • 7LAW R E, MEEHAN W P, XI X P, et al. Troglitazone inhibitsvascular smooth muscle cell growth and intimal hyperplasia[ J]. J Clin Invest, 1996, 98(8) : 1897 -1905.

二级参考文献9

  • 1林成仁,马雪瑛,王敏,庄百溪,刘建勋.通心络胶囊对家兔髂股动脉粥样硬化闭塞症的影响[J].中国中药杂志,2007,32(6):511-515. 被引量:5
  • 2Wilson P W, Kannel W B, Silbershatz H, et al. Clustering of metabolic factors and coronary heart disease [ J ]. Arch Intern Med, 1999, 159(10): 1104.
  • 3Wu Y, Liu X, Li Y, et al. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular disease in Chinese adults [ J ]. Circulation, 2006, 114(6) :2217.
  • 4Yusuf H R, Giles W H, Croft J B, et al. Impact of multiple risk factor profiles on determining cardiovascular disease risk [ J ]. Prey Med, 1998, 27(1) :1.
  • 5Grundy S M, Cleeman J I, Daniels S R, et al. Diagnosis and management of the metabolic syndrome : an american heart association/national heart, lung and blood institute scientific statement [ J ]. Circulation, 2005, 112 (17) : 2735.
  • 6Rader D J. Molecular regulation of HDL metabolism and function : Implications for novel therapies [ J ]. J Clin Invest, 2036, 116(12) : 3090.
  • 7Zhang L, Liu Y, Lu X T, et al. Traditional Chinese medication Tongxinluo dose-dependently enhances stability of vulnerable plaques: A comparison with a high-dose simvastatin therapy[ J]. Am J Physiol Heart Circ Physiol, 2009, 297 (6) : H2004.
  • 8Tang Y D, Kuzman J A, Said S, et al. Low thyroid function leads to cardiac atrophy with chamber dilatation, impaired myocardial blood flow, loss of arterioles, and severe systolic dysfunction[J]. Circulation, 2005, 112(20) : 3122.
  • 9De Groot E, Hovingh G K, Wiegman A, et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis [J]. Circulation, 2004, 109 (23 Suppl 1) : 11133.

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部